Inhibiting PARP as a Strategic Target in Cancer
Poly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell’s ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Media SA
2021
|
| Subjects: | |
| Online Access: | 18342 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1869515059623886848 |
|---|---|
| author | Kristin Zorn Christina Annunziata |
| author_browse | Christina Annunziata Kristin Zorn |
| author_facet | Kristin Zorn Christina Annunziata |
| author_sort | Kristin Zorn |
| collection | Directory of Open Access Books |
| description | Poly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell’s ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have specific defects in DNA repair pathways, and that these defects may predispose for sensitivity and resistance to various classes of cytotoxic agents. Breast, ovarian and other cancers develop in the setting of inherited DNA repair deficiency, and these cancers may be more sensitive to cytotoxic agents that induce DNA strand breaks, as well as to inhibitors of PARP activity. A series of recent clinical trials has tested whether PARP inhibitors can achieve synthetic lethality in hereditary DNA repair-deficient tumors. At the current time, mutation of BRCA serves as a potential, but not comprehensive, biomarker to predict response to PARP inhibitor therapy. Mechanisms of resistance to PARP inhibitors are only recently being uncovered. Future studies seek to identify sporadic cancers that harbor genomic instability rendering susceptibility to PARP inhibitors that compound lethal DNA damage. |
| format | Online |
| id | doab-20.500.12854ir-50258 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-502582024-03-30T23:21:41Z Inhibiting PARP as a Strategic Target in Cancer Kristin Zorn Christina Annunziata R5-920 RC254-282 DNA reapir PARP inhibitor Homologous Recombination combination therapy DNA Damage Cancer thema EDItEUR::M Medicine and Nursing Poly-ADP ribose polymerase (PARP) proteins are critical mediators of DNA repair. Many traditional anti-cancer chemotherapy agents overwhelm a cell’s ability to repair DNA damage in order to kill proliferating malignant cells. Recent evidence suggests that cancers within and across tissue types have specific defects in DNA repair pathways, and that these defects may predispose for sensitivity and resistance to various classes of cytotoxic agents. Breast, ovarian and other cancers develop in the setting of inherited DNA repair deficiency, and these cancers may be more sensitive to cytotoxic agents that induce DNA strand breaks, as well as to inhibitors of PARP activity. A series of recent clinical trials has tested whether PARP inhibitors can achieve synthetic lethality in hereditary DNA repair-deficient tumors. At the current time, mutation of BRCA serves as a potential, but not comprehensive, biomarker to predict response to PARP inhibitor therapy. Mechanisms of resistance to PARP inhibitors are only recently being uncovered. Future studies seek to identify sporadic cancers that harbor genomic instability rendering susceptibility to PARP inhibitors that compound lethal DNA damage. 2021-02-11T16:15:19Z 2021-02-11T16:15:19Z 2016-01-19 14:05:46 2016 book 18342 16648714 9782889199556 https://directory.doabooks.org/handle/20.500.12854/50258 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Inhibiting_PARP_as_a_Strategic_Target_in_Cancer/941 http://journal.frontiersin.org/researchtopic/1263/inhibiting-parp-as-a-strategic-target-in-cancer Frontiers Media SA 10.3389/978-2-88919-955-6 10.3389/978-2-88919-955-6 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889199556 97 open access |
| spellingShingle | R5-920 RC254-282 DNA reapir PARP inhibitor Homologous Recombination combination therapy DNA Damage Cancer thema EDItEUR::M Medicine and Nursing Kristin Zorn Christina Annunziata Inhibiting PARP as a Strategic Target in Cancer |
| title | Inhibiting PARP as a Strategic Target in Cancer |
| title_full | Inhibiting PARP as a Strategic Target in Cancer |
| title_fullStr | Inhibiting PARP as a Strategic Target in Cancer |
| title_full_unstemmed | Inhibiting PARP as a Strategic Target in Cancer |
| title_short | Inhibiting PARP as a Strategic Target in Cancer |
| title_sort | inhibiting parp as a strategic target in cancer |
| topic | R5-920 RC254-282 DNA reapir PARP inhibitor Homologous Recombination combination therapy DNA Damage Cancer thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RC254-282 DNA reapir PARP inhibitor Homologous Recombination combination therapy DNA Damage Cancer thema EDItEUR::M Medicine and Nursing |
| url | 18342 |
| work_keys_str_mv | AT kristinzorn inhibitingparpasastrategictargetincancer AT christinaannunziata inhibitingparpasastrategictargetincancer |